Biosante Pharmaceuticals

DUBLIN, June 30, 2023 /PRNewswire/ -- The "Global Proteomics Partnering Terms and Agreements 2010 to 2023" report has been added to ResearchAndMarkets.com's offering. The Global Proteomics Partnering Terms and Agreements 2010 to 2023 report provides an understanding and access to the proteomics partnering deals and agreements entered into by the world's leading healthcare companies. Trends in proteomics dealmaking in the biopharma industry since 2010 Access to headline, upfront, milestone and royalty data Access to over 600 proteomics deal records and contract documents where available The leading proteomics deals by value since 2010 Most active proteomics dealmakers since 2010 The leading proteomics partnering resources The Global Proteomics Partnering Terms and Agreements report provides an understanding and access to the proteomics partnering deals and agreements entered into by the world's leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter proteomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors proteomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains links to online copies of actual proteomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. For example, analyzing actual company deals and agreements allows assessment of the following: What is actually granted by the agreement to the partner company? What exclusivity is granted? What are the precise rights granted or optioned? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? The initial chapters of this report provide an orientation of proteomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in proteomics dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading proteomics deals since 2010. Deals are listed by headline value, signed by big pharma, most active proteomics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in proteomics dealmaking with a brief summary followed by a comprehensive listing of proteomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive and detailed review of proteomics partnering deals signed and announced since Jan 2010. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of proteomics partnering deals signed and announced since Jan 2010. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided organized by Proteomics partnering company A-Z, deal type definitions and proteomics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in proteomics partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of proteomics technologies and products. Key Topics Covered Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in proteomics dealmaking 2.1. Introduction 2.2. Proteomics partnering over the years 2.3. Most active proteomics dealmakers 2.4. Proteomics partnering by deal type 2.5. Proteomics partnering by therapy area 2.6. Deal terms for proteomics partnering 2.6.1 Proteomics partnering headline values 2.6.2 Proteomics deal upfront payments 2.6.3 Proteomics deal milestone payments 2.6.4 Proteomics royalty rates Chapter 3 - Leading proteomics deals 3.1. Introduction 3.2. Top proteomics deals by value Chapter 4 - Most active proteomics dealmakers 4.1. Introduction 4.2. Most active proteomics dealmakers 4.3. Most active proteomics partnering company profiles Chapter 5 - Proteomics contracts dealmaking directory 5.1. Introduction 5.2. Proteomics contracts dealmaking directory Chapter 6 - Proteomics dealmaking by technology type Appendices Appendix 1 - Proteomics deals by company A-Z Appendix 2 - Proteomics deals by stage of development Appendix 3 - Proteomics deals by deal type Appendix 4 - Proteomics deals by therapy area Deal type definitions Companies Mentioned 3SBio 20/20 BioResponse 21st Century Biochemicals A*STAR Bioinformatics Institute A*STAR Genome Institute of Singapore A*STAR Institute of Microelectronics (IME) AB Analitica Abbvie Abcam Ablynx Abnova Abraxis BioScience Absorption Systems Abt Bio Pharma Solutions Academy for Medical Development & Collaboration Acceleron Pharma Acella Pharmaceuticals ACGT Activiomics ActivX Biosciences ADC Biotechnology Adeona Pharmaceuticals Adimab Aduro BioTech Advaita Advanced Biological Laboratories Advanced BioScience Laboratories Advanced Manufacturing Fund Advinus Therapeutics Aelan Cell Technologies Aestus Therapeutic AEterna Zentaris Affibody Affomix Affymetrix Agilent Technologies AGTC Aileron Therapeutics Ajinomoto AminoScience Alamar Biosciences Albumedix Alexion Pharmaceuticals Allergan Allozyne Almac Diagnostics Almac Group Almirall Alnylam Pharmaceuticals Althea Technologies Altus Pharmaceuticals Alzheimers Research UK Amarantus BioSciences Ambergen Ambrx American College of Cardiology American CryoStem American Health Assistance Foundation Amgen AmorChem Amplimmune Amunix Analytical Testing Laboratory AnaSpec Anchor Therapeutics Angel Biotechnology Anteo Diagnostics Anthera Pharmaceuticals Antigen Discovery Antitope Apeiron Biologics Applied Proteomics Arbor Vita Arbutus Arecor Ariadne Genomics ArmaGen Arrayit Artes Biotechnology Aspera Astellas Pharma AstraZeneca Asuragen ATUM Auburn University Aurigene Discovery Technologies Aushon BioSystems Autism Speaks Autogenesis Auven Therapeutics Avera Heart Hospital of South Dakota Avid Bioservices AvidBiotics Avila Therapeutics Avraham Pharmaceuticals Axil Scientific BaroFold Batavia Biosciences Baxter International Bayer Bayer CropScience Bayer Schering Pharma Baylor College of Medicine BellBrook Labs Bellus Health Berg BGI Americas BG Medicine Bicycle Therapeutics Bill and Melinda Gates Foundation Bio-Techne BioAtla Biocartis Biocius Life Sciences Biocrates Biodesix Bioeasy Diagnostica BioFocus Biogen Biognosys BioGrammatics Biomodels BioNova Cientifica Biopharm BioSante Pharmaceuticals BioSeek Bio Sidus Argentina BioSilta BioSystem Development Biotage Biotechnology and Biological Sciences Research Council (BBSRC) Biotechnology Value Fund Biotest bioVidria BioWa Bioyong BluePen Biomarkers Blue Sky Biotech Boehringer Ingelheim Boehringer Ingelheim Vetmedica BostonGene Bristol-Myers Squibb Bruker Bucher Biotec Bulldog Bio c-LEcta Caladrius Biosciences Caliber Biotherapeutics California Institute for Quantitative Biosciences (QB3) Calixar Cambridge Isotope Laboratories Cambridge Research Biochemicals Camino Partnership Cancer Research Technology Cancer Research UK Cangene Caprion Biosciences Caprion Proteomics Caprotec Bioanalytics For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Stephen Simes career public biotech company CEO and Ryan Dunlap CFO with public biotech company experience join Board VANCOUVER, Wash., Oct. 20, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced additional changes in its Board of Directors (the “Board”). Mr. Stephen Simes, a career public company biotech CEO, was appointed to the Board effective October 13, 2022. Mr. Ryan Dunlap, a current CFO with public company biotech experience, was appointed to the Board effective August 25, 2022. Mr. Simes and Mr. Dunlap join the Board as independent directors of the Company. Also, concurrently with the appointment of Mr. Simes, Dr. Scott Kelly resigned as a director. Dr. Kelly will continue to serve as the Company’s Chief Medical Officer and Head of Business Development. The Board now has five directors, all of whom are independent directors. Mr. Simes is an accomplished public company CEO who led a number of biopharmaceutical companies during his over 40 year career in the industry. He has extensive experience developing and implementing corporate strategies, establishing growth metrics, driving performance, and meeting growth objectives through organic expansion, acquisitions, and partnerships. When CEO at RestorGenex Corporation, Mr. Simes built a successful senior executive leadership team and product development portfolio. He also negotiated the merger of RestorGenex with Diffusion Pharmaceuticals, creating a late-stage oncology-focused biotech company. As CEO at BioSante Pharmaceuticals, Inc., Mr. Simes helped secure significant funding through various financing transactions, acquisitions, and license arrangements. BioSante was later acquired by ANI Pharmaceuticals Inc. At Unimed Pharmaceuticals, Inc., a subsidiary of AbbVie Inc., Mr. Simes built, developed, and successfully led research and development, finance, sales, and commercial activities, significantly expanding the product portfolio and increasing stockholder value. Mr. Dunlap has over 25 years of experience in finance and operations leadership at both public and private companies, with significant expertise in strategy setting, building operational efficiencies and effectiveness, fundraising, financial reporting, SEC compliance, and risk management. He is currently the Chief Financial Officer at Gurobi Optimization, LLC. Prior to joining Gurobi, he spent several years as the CFO and COO for a growth equity-backed molecular diagnostics company and four years as the CFO of a publicly traded biotechnology and pharmaceutical sales company. Earlier in his career, Mr. Dunlap held various financial and operational leadership roles in large, multinational organizations and spent 11 years with a number of public accounting firms, including PricewaterhouseCoopers LLP, KPMG LLP, and Moss Adams LLP, where he provided business assurance and advisory services to both public and private companies, focusing on companies in the life sciences and technology industries. Mr. Simes said, “I have been impressed with the new management team and Board of Directors. I believe I can add my biopharma experience and expertise to help build a successful company and improve stakeholder value, while bringing an important product to patients in need.” Mr. Dunlap said, “I’m happy to be a part of the CytoDyn Board and to contribute to a governance environment that garners shareholder trust and keeps the corporate focus on the strategic potential of our asset.” Cyrus Arman, Ph.D., President of CytoDyn, stated, “The appointments of Mr. Simes and Mr. Dunlap further enhance the independence of our Board and add to its biotechnology industry experience. Each of these individuals brings unique skill sets to our Board and will be critical to the Company’s continued success and transformation. We are grateful to Dr. Kelly for his service as a Director and former Chairman of the Board.” About CytoDyn CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. CytoDyn is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions. Forward-Looking Statements This press release may contain certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, as well as risk factors or cautionary statements included in subsequent Form 10-Qs and Form 8-Ks, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release. CONTACTS Investors: Cristina De Leon Office: 360.980.8524 ir@cytodyn.com Media: Joe Germani / Miller Winston Longacre Square Partners jgermani@longacresquare.com / mwinston@longacresquare.com

Dublin, April 29, 2021 (GLOBE NEWSWIRE) -- The "Nanobiotechnology Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering. Nanobiotechnology deals with biological and biochemical applications or applications. Nanobiotechnology mostly studies existing elements of living organisms and nature to fabricate new nano-devices. The potential uses and benefits of nanotechnology are vast. The major applications of nanobiotechnology exist in biomedical field and are primarily targeted towards development of novel drug delivery systems, and it is expected to remain the major application of nanobiotechnology throughout the forecast period.For the purpose of this study, the global nanobiotechnology market on the basis of technology type is segmented into nanoparticles, nanocrystals, quantum dots, liposomes, polymer structures dendrimers, nanopores, and intergrated nanostructures. Market size estimates and forecast for these segments for the period 2019 to 2029 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2016 to 2023, considering 2020 as the base year.On the basis of application type nanobiotechnology market is segmented as drug delivery, sequencing, biologic imaging, research tools and microbicide. Market size estimates and forecast for these segments for the period 2019 to 2029 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2021 to 2029, considering 2020 as the base year.The nanobiotechnology market has been geographically categorized into major regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geography market is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, and GCC countries. Market size and forecast for these segments during 2019 to 2029 and their CAGRs for the period 2021 to 2029 are provided in this report.The major key players profiled in the nanobiotechnology market are on the basis of various characteristics such as business description, financial health and budget allocation, product portfolio, and news coverage. The key players profiled in this report are Aduro BioTech, Calando Pharmaceuticals Inc., Baxter International, Inc., Fresinuns Kabi AG, Smith & Nephew plc, Biosante Phosphate Pharmaceuticals Inc., Celgene Corporation, Elan Pharmaceuticals Inc., Flamel Technologies Inc., Nanophase Technologies Corporation, Sigma Aldrich Company, Dendritic Nanotechnologies Inc. and SkyePharma Pharmaceuticals.Based on the type of application, the global nanobiotechnology market is segmented as follows: On the basis of application nanobiotechnology market is segmented into drug delivery, sequencing, biologic imaging, research tools and microbicide. In base year 2020, drug delivery and sequencing segments were observed as the largest segments of nanobiotechnology accounted for the market share of around 55%. Biotechnology and pharmaceutical industries are expected to remain the largest end-users of nanobiotechnology. Market experts suggested that drug delivery is the most crucial pharmaceutical application and now is the most focused area in nanobiotechnology. In drug delivery application apart from solving solubility issues of drug it also assists to enhance intracellular delivery possibilities and the level of skin permeability in transdermal drug delivery. Thus, nanobiotechnology possesses the potential to develop breakthrough interface systems that allows interaction between novel electronic devices and biological systems.Based on the type of technology, the nanobiotechnology market is segmented into: In base year 2020, the segments liposomes and polymer structure dendrimers collectively account for the major market share of around 50% and are expected to maintain market dominance throughout the forecast period. The rising prevalence of cancer, increasing public awareness related to novel treatments for cancer, and constant technological upgradation in the field of nanotechnology research and development. The major restrains of this market especially in emerging and underdeveloped economies are scarcity of resources and mounting technological cost. However, rising demand from pharmaceutical domain is expected to open up novel growth opportunities within the forecast period. Market experts suggest that nanobiotechnology also possess the capability to develop breakthrough interface systems between physical objects and living cells to allow interaction of modern electronic devices with biological systems. The decades of in-depth research and development in nanobiotechnology is now assisting access to novel avenues of healthcare such as synthesis of advanced nanofabricated systems and devices for treating several untreatable diseases.For the purpose of this study, the global nanobiotechnology market is categorized into: In base year 2020, North America accounted for the largest share in the global nanobiotechnology market, followed by Europe, Asia-Pacific, LATAM and MEA. The Asia-Pacific region (comprising Japan, China and India as major countries) is anticipated to grow at the fastest CAGR during the forecast period 2016 - 2023. The key factors assisting the growth of nanobiotechnology market in North America and Europe are such as rising prevalence of cancer, high acceptance rate in case of novel mode of treatments, high accessibility to advanced healthcare infrastructure and favorable environment for nanobiotechnology-based research and development. Asia-Pacific was observed as the fastest growing region throughout the forecast period 2021 - 2029 due to rising public awareness related to cancer diagnosis and treatment, developing healthcare services and research and development infrastructure, and high market penetration and acceptance of novel treatment technologies. The major restrains of this market especially in emerging and underdeveloped economies are scarcity of resources and mounting technological cost. However, rising demand from pharmaceutical domain is expected to open up novel growth opportunities within the forecast period. Key Topics Covered: Chapter 1 PrefaceChapter 2 Executive Summary2.1 Global Nanobiotechnology Market, by Technology Type, 2020 v/s 2029 (Value %)2.2 Global Nanobiotechnology Market, by Application Type, 2020 (USD Mn)2.3 Global Nanobiotechnology Market, by Geography, 2020 (Value %)Chapter 3 Global Nanobiotechnology Market Overview3.1 Overview3.2 Market Drivers3.3 Market Restraints3.4 Market Opportunities3.5 Attractive Investment Proposition3.6 Market Competition Assessment: Nanobiotechnology Market, by Key PlayersChapter 4 Global Nanobiotechnology Market Analysis, By Technology Type4.1 Overview4.2 Bio-nanomaterials4.3 Nanoparticles4.4 Nanocrystals4.5 Quantum dots4.6 Liposomes4.7 Polymer Structures Dendrimers4.8 Nanopores4.9 Integrated NanostructuresChapter 5 Global Nanobiotechnology Market Analysis, By Applications5.1 Overview5.2 Drug Delivery5.3 Sequencing5.4 Biologic Imaging5.5 Research Tools5.6 MicrobicideChapter 6 Global Nanobiotechnology Market Analysis, By Geography6.1 Preface6.2 North America6.3 Europe6.4 Asia Pacific6.5 Latin America6.6 Middle East and AfricaChapter 7 Company Profiles7.1 Aduro BioTech7.1.1 Aduro BioTech: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)7.2 Calando Pharmaceuticals Inc.7.2.1 Calando Pharmaceuticals Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)7.3 Baxter International, Inc.7.3.1 Baxter International, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)7.4 Fresinuns Kabi AG7.4.1 Fresinuns Kabi AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)7.5 Smith & Nephew plc7.5.1 Smith & Nephew plc: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)7.6 Biosante Phosphate Pharmaceuticals Inc.7.6.1 Biosante Phosphate Pharmaceuticals Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)7.7 Celgene Corporation7.7.1 Celgene Corporation: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)7.8 Elan Pharmaceuticals Inc.7.8.1 Elan Pharmaceuticals Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)7.9 Flamel Technologies Inc.7.9.1 Flamel Technologies Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)7.10 Nanophase Technologies Corporation7.10.1 Nanophase Technologies Corporation: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)7.11 Sigma Aldrich Company7.11.1 Sigma Aldrich Company: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)7.12 Dendritic Nanotechnologies Inc.7.12.1 Dendritic Nanotechnologies Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)7.13 SkyePharma Pharmaceuticals7.13.1 SkyePharma Pharmaceuticals: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)For more information about this report visit